750 completed, 252 terminated, 168 recruiting, 126 unknown. 1525 Phase 1, 499 Phase 2.
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-11-02 |
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers huCART19-IL18-CD428z cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | University of Pennsylvania | 6 | 2027-01-01 | 2026-11-02 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-11-02 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2026-12-01 | 2026-10-22 |
| A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) LP-118 - Philadelphia Positive Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Wake Forest University Health Sciences | 26 | 2026-12-01 | 2026-10-29 |
| A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia Revumenib, Blinatumomab - Blinatumomab, Revumenib | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2026-11-18 | 2026-08-12 |
| Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) TSLPR-CART, Cyclophosphamide, Fludarabine - B-All, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 57 | 2026-11-15 | 2026-11-10 |
| A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment Revumenib - Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia | Phase 1 | Not yet recruiting | Syndax Pharmaceuticals | 18 | 2026-11-01 | 2026-11-06 |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies aldesleukin, cyclophosphamide, fludarabine phosphate - Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-10-28 | 2026-11-02 |
| Prophylactic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | University of Arizona | 180 | 2026-10-26 | 2026-10-29 |
| CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine - Relapsed Pediatric ALL, Hematopoietic Cell Transplantation | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 70 | 2026-10-03 | 2026-08-28 |
| HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Capivasertib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Not yet recruiting | Princess Maxima Center for Pediatric Oncology | 42 | 2026-10-01 | 2025-09-16 |
| A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia zeprumetostat - Large Granular Lymphocyte Leukemia, T-LGL Leukemia | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-10-01 | 2026-11-04 |
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 150 | 2026-09-30 | 2026-11-03 |
Showing 20 of 1525. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (838) · Leukemia, Lymphocytic, Chronic, B-Cell (794) · Lymphoma, Non-Hodgkin (441) · Leukemia, Myeloid, Acute (407) · Leukemia (368) · Lymphoma, Mantle-Cell (358) · Lymphoma, Follicular (352) · Lymphoma, Large B-Cell, Diffuse (332) · Lymphoma (314) · Lymphoma, B-Cell, Marginal Zone (300) · Burkitt Lymphoma (292) · Myelodysplastic Syndromes (224) · Hodgkin Disease (221) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (213) · Lymphoma, Large-Cell, Immunoblastic (196)
Hemic and Lymphatic Diseases (1524) · Immunoproliferative Disorders (1519) · Neoplasms by Histologic Type (1519) · Lymphatic Diseases (1517) · Hematologic Diseases (1516) · Immune System Diseases (1512) · Lymphoproliferative Disorders (1503) · Neoplasms (1450) · Leukemia (1157) · Pathological Conditions, Signs and Symptoms (1036) · Pathologic Processes (1035) · Disease Attributes (1024) · Chronic Disease (935) · Leukemia, B-Cell (767)
Cyclophosphamide (187) · Rituximab (123) · fludarabine (120) · fludarabine phosphate (112) · Cytarabine (91) · Dexamethasone (59) · Filgrastim (59) · venetoclax (59) · Vincristine (58) · Methotrexate (57) · Peripheral Blood Stem Cell Transplantation (53) · ibrutinib (50) · Etoposide (48) · Lenalidomide (46) · Bortezomib (38)
National Cancer Institute (NCI) (151) · M.D. Anderson Cancer Center (74) · Fred Hutchinson Cancer Center (42) · City of Hope Medical Center (31) · Memorial Sloan Kettering Cancer Center (30) · Baylor College of Medicine (22) · Dana-Farber Cancer Institute (20) · St. Jude Children's Research Hospital (20) · Mayo Clinic (18) · Gilead Sciences (17) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (17) · Masonic Cancer Center, University of Minnesota (16) · Novartis Pharmaceuticals (16) · Therapeutic Advances in Childhood Leukemia Consortium (15) · AbbVie (14)
United States (1120) · China (165) · Canada (89) · France (83) · Australia (79) · Spain (78) · Germany (73) · Italy (72) · United Kingdom (72) · Netherlands (40) · Japan (39) · Israel (33) · South Korea (33) · Poland (32) · Belgium (23)
Jae Park, MD (7) · Brenda Sandmaier (6) · James N Kochenderfer, M.D. (5) · Mario Sznol, MD (5) · Michael Choi, MD (5)
PMID 34515338, PMID 41671463, PMID 34398557, PMID 32499241, PMID 24615776, PMID 24615777, PMID 28054442, PMID 35622074, PMID 40195173, PMID 41429239, PMID 19238148, PMID 19949018, PMID 20028764, PMID 20882050, PMID 21816833, PMID 22002018, PMID 23886836, PMID 24055823, PMID 24615778, PMID 24782509, PMID 25317870, PMID 25381051, PMID 26182309, PMID 26813675, PMID 27482888, PMID 29296805, PMID 31023700, PMID 31723767, PMID 33067379, PMID 33741715, PMID 33883258, PMID 34267079, PMID 34608724, PMID 34687939, PMID 34780125, PMID 34889384, PMID 35126471, PMID 35799791, PMID 36375120, PMID 36858787, PMID 37486616, PMID 39368878, PMID 39563886, PMID 39863139, PMID 40233328, PMID 40246579, PMID 40472301, PMID 41258689, PMID 42411504, PMID 42541678
P30CA033572 (21), P30CA015704 (20), U01CA076576 (16), 2023 (13), U01CA070095 (13), P30CA006973 (12), P30CA016672 (12), U01CA069912 (11), U01CA097452 (11), P30CA015083 (10), 2015 (9), P30CA016058 (9), U01CA062461 (9), 2014 (8), 2018 (8)